Product
INCB054707
Aliases
Povorcitinib
8 clinical trials
6 indications
Indication
Chronic Kidney DiseaseIndication
Kidney DiseasesIndication
VitiligoIndication
Prurigo NodularisIndication
Healthy ParticipantsIndication
Hidradenitis SuppurativaClinical trial
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on HemodialysisStatus: Completed, Estimated PCD: 2024-02-07
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With VitiligoStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisStatus: Active (not recruiting), Estimated PCD: 2023-08-11
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2019-04-22
Clinical trial
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2019-08-13
Clinical trial
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese ParticipantsStatus: Completed, Estimated PCD: 2022-01-25
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2021-12-15